金吾财讯 | 创新药概念股集体走强,截至发稿,药明康德(02359)涨7.46%,同源康医药-B(02410)涨6.96%,药明合联(02268)涨6.38%,华昊中天医药-B(02563)涨5.48%,恒瑞医药(01276)涨3.29%,博安生物(06955)涨3.20%。消息面上,高盛数据显示,截至2025年上半年,中国贡献了全球50%的新进入人体临床的新药分子,并拥有约1/3的全球创新药在研管线。十年前,这一占比仅为个位数。尤其是在ADC(抗体偶联药物)、BsAb(双特异抗体)等新型药物形式上,中国已成为全球最重要的创新来源之一。报告指出,截至目前,中国生物科技公司整体市值仍仅为美国同行的14%-15%,而其在全球创新贡献中的比重已接近33%。这意味着,中国创新药板块仍处于“价值洼地”阶段,全球资本重估才刚刚开始。
高盛认为,中国生物科技行业正在经历一次结构性重估,本轮大涨并非短期反弹。截至目前,中国生物科技公司整体市值仍仅为美国同行的14%-15%,而其在全球创新贡献中的比重已接近33%。这意味着,中国创新药板块仍处于“价值洼地”阶段,全球资本重估才刚刚开始。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.